Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-10155032-B2
Application number	US-201715638072-A
Country	US
Kind code	B2
Filing date	Jun 29, 2017
Priority date	Aug 5, 2015
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has prostate cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide,
wherein said peptide consisting of the amino acid sequence of AYSEKVTEF (SEQ ID NO: 54),
wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide, and
wherein the antigen presenting cell is a particle coated with the peptide in a complex with an MHC class I molecule.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , further comprising expanding T cells in vitro.

6. The method of claim 1 , wherein the MHC molecule is a class I molecule.

7. The method of claim 1 , wherein the composition further comprises an adjuvant.

8. The method of claim 7 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG, oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with PLG and virosomes.

9. The method of claim 1 , further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells.

10. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.

11. The method of claim 1 , wherein the contacting is in vitro.

12. The method of claim 1 , wherein the particle is further coated with an anti-CD28 antibody.

13. The method of claim 1 , wherein the particle is polystyrene particle.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Mueller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• G01N2570/00

  Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes · CPC title

• G01N33/6848

  Methods of protein analysis involving mass spectrometry · CPC title